Sleep-eze® eze-melts, which contain 25mg of diphenhydramine hydrochloride, was developed and licensed by Eurand using its AdvaTab® and Microcaps® taste-masking technologies. Sleep-eze® eze-melts, an OTC sleep-aid, was successfully launched in August 2010 and is now available in leading Canadian mass merchandiser, drug and food retailers. Eurand supplies the Sleep-eze® eze-melts product exclusively for Prestige Brands. The product is manufactured at Eurand’s US facility in Vandalia, Ohio.

Prestige Brands Holdings, Inc. markets and sells well-recognised, brand name consumer over-the-counter healthcare and household cleaning products throughout the US, Canada and certain international markets. The company operates in niche segments within these categories in which the strength of the brand names, the established retail distribution network, a low cost operating model, and an experienced management team are keys to success. AdvaTab® Product Portfolio Eurand’s AdvaTab technology can also be applied to products in the prescription (Rx) category, most notably with the 2009 GlaxoSmithKline launch of LAMICTAL® ODT™ (lamotrigine) orally disintegrating tablets, indicated for epilepsy as adjunctive therapy in patients ≥2 years of age ; epilepsy as monotherapy in patients ≥16 years of age; and bipolar disorder in patients ≥18 years of age. Lamictal ODT is available in 25mg, 50mg, 100mg and 200mg strengths as a fruity-flavored tablet that disintegrates in the mouth and can be taken with or without food or water.

Continuing OTC product development, Eurand is offering licensing opportunities for AdvaTab Acetaminophen (also known as paracetamol), incorporating Eurand’s expertise to mask the notably bitter-tasting drug. AdvaTab® Acetaminophen is an immediate-release product that is formulated in a range of dosing strengths for both pediatric and adult consumers (80mg – 500mg). The convenient, easy-to-swallow dosage form can be taken with or without water and disintegrates within 30sec in compliance with FDA guidelines. The acetaminophen formulation complies with the USP monograph; therefore, scale-up to launch could be completed for a partner in as little as six months (conditions apply).